Yul Ri Chung

1.5k citations
48 papers · 1.1k indexed · h-index 21
Topics
Breast Cancer Treatment Studies (13 papers)HER2/EGFR in Cancer Research (10 papers)Cancer Cells and Metastasis (8 papers)

In The Last Decade

Yul Ri Chung

47 papers receiving 1.1k citations

Peers

Yul Ri Chung
Comparison fields: 5 of 78
  • Cancer Research 497
  • Oncology 492
  • Molecular Biology 426
  • Pulmonary and Respiratory Medicine 133
  • Pathology and Forensic Medicine 132
Replace Xianyu Zhang with:
Xianyu Zhang China
Ellen Hollywood United States
Francesco Merolla Italy
Esther M. de Kruijf Netherlands
Yoshiya Horimoto Japan
Sasagu Kurozumi Japan
Thomas B. Karasic United States
Lian Xu China
Zahra Mohammed United Kingdom
Lydia Gaba Spain
Yul Ri Chung relative to Xianyu Zhang China Xianyu Zhang's profile →
Citations per field
00.5×1.7×
Xianyu Zhang · 1×
Citations per year

Countries citing papers authored by Yul Ri Chung

Since Specialization
Citations

This map shows the geographic impact of Yul Ri Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yul Ri Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yul Ri Chung more than expected).

Fields of papers citing papers by Yul Ri Chung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yul Ri Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yul Ri Chung. The network helps show where Yul Ri Chung may publish in the future.

Co-authorship network of co-authors of Yul Ri Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Yul Ri Chung. A scholar is included among the top collaborators of Yul Ri Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yul Ri Chung. Yul Ri Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 5
3 12
4 24
5 31
6 36
7 15
8 21
9 6
10 38
11 59
12 10
13 25
14 56
15 21
16 117
17 34
18 24
19 118
20
In vivo Biocompatibility and Stability of Polyimide Microelectrode Array for Retinal Stimulation
1

About Yul Ri Chung

Yul Ri Chung is a scholar working on Cancer Research, Oncology and Geriatrics and Gerontology, having authored 48 papers that have together received 1.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Cells and Metastasis (8 papers). The work is most often cited by research in Cancer Research (497 citations), Geriatrics and Gerontology (75 citations) and Oncology (492 citations). Yul Ri Chung has collaborated with scholars based in South Korea, Puerto Rico and Ethiopia. Frequent co-authors include So Yeon Park, Hyun Jeong Kim, Min Hye Jang, Jae Moon Gwak, Milim Kim, Eun Joo Kim, Han Suk Ryu, Ji Won Woo, Soomin Ahn and An Na Seo. Their work appears in journals such as PLoS ONE, Scientific Reports and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026